Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Strikes Out At Supreme Court As Three Recent Cert Petitions Fail

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer, Cephalon and former InterMune CEO Scott Harkonen will find no relief from the high court.

You may also be interested in...

Regeneron's Patent Pratfall: First Inequitable Conduct, Now Possible Sanctions

After losing patent infringement suit against Merus involving antibody-producing mouse, Regeneron fights ruling that it withheld material information in prosecuting the patent.

Appeals Court Revives RICO Off-Label Suit Against Abbott

Seventh Circuit reinstates employer benefit funds’ complaint over off-label promotion of Depakote, allowing them to make case they were not properly compensated; courts have issued disparate opinions in such cases.

Off-Label Is Off The Docket: Supreme Court Leaves RU-486 Flexibility Intact

High court declines to intervene in dispute over Arizona law that would restrict use of abortion drug; court also denies Roche petition for review of Boniva patent ruling.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts